Intermediate for Vorapaxar. Vorapaxar (trade name: Zontivity) is a thrombin receptor (protease-activated receptor, PAR-1) antagonist. Vorapaxar is a new anti-platelet drug that and is used for persons with a history of myocardial infarction (heart attack) or persons with peripheral arterial disease. Vorapaxar has been approved by the U.S Food and Drug Administration on May 5, 2014.
Product Name: (E)-3-(1,4-Dioxaspiro[4.5]dec-7-en-7-yl)acrylic acid
CAS Number: 226916-19-4
Molecular Weight:  210.2292
Molecular Formula:  C11H14O4
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.